Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;26(12):1109-1128.
doi: 10.1016/j.jmoldx.2024.08.006. Epub 2024 Sep 24.

Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer

Affiliations
Free article

Colocalization of Cancer-Associated Biomarkers on Single Extracellular Vesicles for Early Detection of Cancer

Daniel P Salem et al. J Mol Diagn. 2024 Dec.
Free article

Abstract

Detection of cancer early, when it is most treatable, remains a significant challenge because of the lack of diagnostic methods sufficiently sensitive to detect nascent tumors. Early-stage tumors are small relative to their tissue of origin, heterogeneous, and infrequently manifest in clinical symptoms. The detection of early-stage tumors is challenging given the lack of tumor-specific indicators (ie, protein biomarkers, circulating tumor DNA) to enable detection using a noninvasive diagnostic assay. To overcome these obstacles, we have developed a liquid biopsy assay that interrogates circulating extracellular vesicles (EVs) to detect tumor-specific biomarkers colocalized on the surface of individual EVs. We demonstrate the technical feasibility of this approach in human cancer cell line-derived EVs, where we show strong correlations between assay signal and cell line gene/protein expression for the ovarian cancer-associated biomarkers bone marrow stromal antigen-2, folate receptor-α, and mucin-1. Furthermore, we demonstrate that detecting distinct colocalized biomarkers on the surface of EVs significantly improves discrimination performance relative to single biomarker measurements. Using this approach, we observe promising discrimination of high-grade serous ovarian cancer versus benign ovarian masses and healthy women in a proof-of-concept clinical study.

PubMed Disclaimer

Conflict of interest statement

Disclosure Statement D.P.S., L.T.B., I.O.Z., A.D.C., S.B., D.M.B., M.S.K., L.T.C., T.S.-H., G.N.B., K.S.Y., T.G., and D.R.M. are current employees of Mercy BioAnalytics Inc. E.S.W.-D. is a retired Mercy BioAnalytics employee (December 31, 2023) and is currently a paid consultant of Mercy BioAnalytics Inc. She was a full-time employee when this work was performed. K.M.B., P.A.D., J.G., D.G., B.F.H., E.K.H., C.R.S., and J.C.S. are former employees of Mercy BioAnalytics Inc., who were active employees at the time this work was performed. R.W.S. is a paid consultant of Mercy BioAnalytics. L.T.B. and D.P.S. are inventors on US patent number 11,085,089 B2, Systems, Compositions and Methods for Target Entity Detection (issued August 10, 2021). L.T.B., D.P.S., E.S.W.-D., D.G., K.M.B., E.K.H., and A.D.C. are inventors on US patent application 63/417309, Composition and Methods for Detection of Ovarian Cancer (filed October 18, 2022).

LinkOut - more resources